Anavex Life Sciences (NASDAQ: AVXL) and Grifols SA, Barcelona (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Insider and Institutional Ownership
22.7% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 22.5% of Grifols SA, Barcelona shares are owned by institutional investors. 11.6% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for Anavex Life Sciences and Grifols SA, Barcelona, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||2||0||3.00|
|Grifols SA, Barcelona||0||1||3||0||2.75|
Anavex Life Sciences presently has a consensus price target of $14.50, suggesting a potential upside of 355.97%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Grifols SA, Barcelona.
Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Anavex Life Sciences does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.
Volatility & Risk
Anavex Life Sciences has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Grifols SA, Barcelona has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Valuation & Earnings
This table compares Anavex Life Sciences and Grifols SA, Barcelona’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anavex Life Sciences||N/A||N/A||-$13.46 million||($0.33)||-9.64|
|Grifols SA, Barcelona||$4.48 billion||3.34||$603.60 million||$0.93||23.60|
Grifols SA, Barcelona has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.
This table compares Anavex Life Sciences and Grifols SA, Barcelona’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-70.10%||-63.39%|
|Grifols SA, Barcelona||13.16%||18.08%||6.22%|
Grifols SA, Barcelona beats Anavex Life Sciences on 9 of the 14 factors compared between the two stocks.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
About Grifols SA, Barcelona
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.